ERBB2 and breast carcinoma: Using multiple HER2+ breast cancer cell lines, Levine lab showed that HER2 and BECN1 interact, and that such interaction is dependent on the HER2 activity, as a kinase-dead mutant of HER2 failed to co-immunoprecipitate with BECN1 (Vega-Rubin-de-Celis et al., 2018).